PepGen Inc.
BOSTON, MA · Founded 2020 · CIK 0001835597 · Biotech · Public
disease-modifying therapeutics targeting genetic neuromuscular and neurological diseases
pepgen.com →- Grants
- —
- No SBIR or STTR on record
- Sector median 1 award
- Raised
- $127M
- 2 Form D · Aug 2021
- 62 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 14
- 0 granted · 14 pending
- 7.0× sector median 2 patents
Capital Timeline
Federal ↑Equity ↓202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $112,499,887 | |
| Private capital raised | Form D · SEC | $14,366,712 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3380 | BlossomHill Therapeutics | — | $246M |
| 3381 | Shattuck Labs, Inc. | — | $164M |
| 3382 | Colossal Biosciences | — | $150M |
| 3383 | PepGen Inc. | — | $127M |
| 3384 | MouSensor, Inc. | — | — |
| 3385 | AGEX THERAPEUTICS INC | — | $19M |
| 3386 | Ultragenyx Pharmaceutical Inc. | — | $109M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Christopher AshtonDirector
- Ramin Farzaneh-FarDirector
- Caroline GodfreyDirector · Executive Officer
- Heidi HensonDirector
- James McArthurDirector · Executive Officer
- Josh ResnickDirector
- Joshua ResnickDirector
- Matthew WoodDirector
Patents
- Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-oligonucleotide Conjugatesapplication
- Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
- Cell-penetrating Peptides, Conjugates Thereof, And Methods Of Their Useapplication
- Methods And Compositions For Treating Duchenne Muscular Dystrophyapplication
- Antisense Oligonucleotide Conjugates Targeting Peripheral Myelin Protein 22 (PMP22) And Methods Of Use Thereofapplication
- Cell-penetrating Peptides, Conjugates Thereof, And Methods Of Their Useapplication
- Cell-penetrating Peptide Conjugates And Methods Of Their Useapplication
- Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-ologonucleotide Conjugatesapplication
- Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
- Methods Of Treating Duchenne Muscular Dystrophy Using Peptide-oligonucleotide Conjugatesapplication
- Methods Of Treating Myotonic Dystrophy Type 1 Using Peptide-oligonucleotide Conjugatesapplication
- Methods And Compositions For Treating Duchenne Muscular Dystrophyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.